Biologiques et lupus érythémateux systémique : nouveautés et perspectives [Biologics and systemic lupus erythematosous : new insights and perspectives]
Fiche du document
7 avril 2021
- doi: 10.53738/REVMED.2021.17.733.0684
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2021.17.733.0684
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33830700
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/grantAgreement/SNF/Careers/PZ00P3_173950///
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_F63846A94F199
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Therapy Biologics Lupus vulgarisCiter ce document
A. Clottu et al., « Biologiques et lupus érythémateux systémique : nouveautés et perspectives [Biologics and systemic lupus erythematosous : new insights and perspectives] », Serveur académique Lausannois, ID : 10.53738/REVMED.2021.17.733.0684
Métriques
Partage / Export
Résumé
Systemic lupus erythematosus is a complex autoimmune disease that remains challenging to treat. Recent advances in the understanding of the pathogenesis of SLE pave the way for the evaluation of biologic medicine. The most promising therapeutic targets in SLE are those that interfere with B cells count or normal function, interferon inhibitors, JAK inhibitors and biologicals that alter the cytokines imbalance that characterizes SLE. Recent phase 3 clinical trials have evaluated the role of belimumab in lupus nephritis and the usefulness of anifrolumab in the treatment of moderate to severe SLE. Many more trials are currently underway and may improve the level of care of patients with SLE in the near future.